MedReleaf, North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, announced a milestone achievement with the completion of its first international export. The transaction is also noteworthy as the first ever import of medical cannabis oil to Brazil.
The export is being made to treat the symptoms of Sofia Langenbach, a child who carries the CDKL5 genetic syndrome – leading her to experience refractory epilepsy and severe seizures which for her, has only been alleviated by the use of medical cannabis. Her mother, Ms. Margarette Santos de Brito, currently president of APEPI ("Support for Research and Medical Cannabis Patients"), the first and largest Association of Cannabis patients in Brazil, previously won a landmark Brazilian court case to cultivate her own cannabis and has been one of the leading activists advocating for the legalization of medical cannabis in Brazil for many years.
"We have been working with Margarette Santos De Brito (president of Brazilian NGO APEPI), who has been a tireless, high-profile public champion of medical cannabis and whose daughter Sofia is in dire need of cannabis-based pharmaceutical products to manage her symptoms", said Neil Closner, CEO of MedReleaf. "We are proud that Ms. Santos and ANVISA, the Brazilian Government's National Health Surveillance Agency, have put their faith in MedReleaf."
"This is an important step in achieving MedReleaf's goals of ensuring that patients in need around the world receive the highest quality cannabis-based pharmaceutical products available and in realizing our long-term growth plans", continued Closner.
"I am very thankful we received this first import of MedReleaf's medical grade cannabis oil for Sofia", said Ms. Santos.
For more information:
medreleaf.com
Sign up for our daily Newsletter and stay up to date with all the latest news!
Subscribe I am already a subscriber